SAN FRANCISCO and SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported positive topline results from its randomized, head-to-head Phase 1b JADE clinical study comparing IBI324 (Olli ...

Core Insights - Innovent Biologics, in partnership with Ollin, is advancing IBI324 (OLN324), a bispecific antibody targeting VEGF and Ang2, currently in Phase 1b clinical trials for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) [1][2][3] - The JADE study has enrolled over 150 patients, with topline results expected in Q1 2026, indicating significant progress in the clinical development of OLN324 [1][3] Company Overview - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on developing high-quality medicines for various diseases, including oncology and ophthalmology [5] - The company has launched 16 products and has multiple assets in various stages of clinical trials, showcasing a robust pipeline [5] Product Development - OLN324 is designed to have higher potency and durability compared to the current market leader, faricimab, potentially establishing it as a first-line treatment option [2][3] - The dual targeting mechanism of OLN324 aims to improve clinical outcomes for patients suffering from wAMD and DME, addressing significant unmet medical needs [3][2] Clinical Trial Progress - The successful completion of patient enrollment in the JADE study marks a key milestone for both Innovent and Ollin, reflecting their strong collaboration [3][1] - Previous studies have shown promising results for IBI324 in improving vision and anatomical outcomes in DME patients, alongside a favorable safety profile [3]